ObjectiveTo systematically review the diagnostic value of the combined test of serum CA153, CA125 and CEA in detection of breast cancer. MethodsClinical diagnostic tests about CA153, CA125 and CEA in patients with breast cancer were retrieved in PubMed, EMbase, CBM, The Cochrane Library (Issue 3, 2014), CNKI, VIP, and WanFang Data from January 1st, 2004 to April 16st, 2014. References of included literature were also retrieved. Literature screening according to the inclusion and exclusion criteria, data extraction and methodological quality assessment were completed by two reviewers independently. Meta-analysis was then conducted using Meta-Disc 1.4 software. ResultsA total of 21 studies involving 4 263 subjects were enrolled. In all studies, the results of meta-analysis indicated that:the DOR, AUC and Q index of the single test (CA153) were 18.71 (95%CI 11.62 to 30.11), 0.858 9, and 0.789 7; while those of the combined test (CA153, CA125 and CEA) were 37.95 (95%CI 21.97 to 65.57), 0.959 1, 0.903 1. Compared with the single test, the diagnostic efficacy of the combined test was higher (Z=3.675, P=0.001 5). ConclusionCompared with the detection of CA153 alone, the combined detection of CA125, CA153 and CEA has higher efficacy and accuracy in the diagnosis of breast cancer.
【摘要】目的探討骨橋蛋白(OPN)聯合血清CA125和CA199水平對子宮內膜異位癥的診斷價值。方法2005年1月2008年12月采集45例子宮內膜異位癥患者及45名健康婦女自愿捐贈的血清樣品,分別采用ELISA法及化學發光法檢測OPN、CA125、CA199水平。結果與健康婦女相比,子宮內膜異位癥患者血清OPN和CA125、CA199含量明顯升高(Plt;001)。重度組(美國生育學會分期Ⅲ、Ⅴ期)子宮內膜異位癥患者OPN和CA125、CA199明顯高于輕度組(Ⅰ、Ⅱ期)(Plt;001)。結論OPN、CA199可作為子宮內膜異位癥診斷及病情監測的臨床指標,聯合CA125檢測可提高其臨床應用價值。
目的探討血清CA153、CA125和CA19-9檢測對乳腺癌早期診斷的價值。方法采用化學發光免疫法分別檢測乳腺癌、乳腺良性疾病患者及正常健康體檢者血清CA153、CA125和CA19-9的水平。結果乳腺癌患者血清的CA153、CA125和CA19-9的表達水平及表達陽性率均明顯高于正常對照者和乳腺良性疾病患者(Plt;0.01)； 乳腺癌患者術后CA153、CA125及CA19-9表達水平較術前明顯下降(Plt;0.01)，與正常對照者比較差異無統計學意義(Pgt;0.05)。結論腫瘤標志物CA153、CA125及CA19-9 對乳腺癌有一定的診斷價值，且可作為監測乳腺癌病情進展、評估治療療效及預后的指標。